Printed from the Field Fisher Waterhouse web site
Web address: http://www.ffw.com/publications/all/articles/pharmaceutical-advertising.aspx

Find a publication

Click on one, or a combination of menus below to locate the publications you are looking for.




Cancel Search


RSS publication feeds

Contacts

Related practices

Related sectors

Related offices

Icons Key

<global:term runat=server TermName='icons_alerts' />Alerts

<global:term runat=server TermName='icons_articles' />Articles

<global:term runat=server TermName='icons_books' />Books

<global:term runat=server TermName='icons_papers' />Briefing papers

<global:term runat=server TermName='icons_newsletters' />Newsletters

<global:term runat=server TermName='icons_podcasts' />Podcasts

Practices

The International Comparative Legal Guide to: Pharmaceutical Advertising 2012 Edition

28 June 2012

This article appeared in the 2012 edition of The International Comparative Legal Guide to: Pharmaceutical Advertising; published by Global Legal Group Ltd , London. http://www.iclg.co.uk/

The International Comparative Legal Guide to: Pharmaceutical Advertising 2012
9th Edition

A practical cross-border insight into pharmaceutical advertising

Pharmaceutical Promotion and the UK Bribery Act

The Bribery Act came into force on 1 July 2011. Together with explanatory guidance published by the Ministry of Justice in March 2011, the new law replaced the outdated UK anti-bribery legislation which was over 100 years old. The UK was required to implement modern anti-bribery legislation by the OECD Convention it ratified in 1999. However, the 2002 enactments by the UK did not to fully achieve this goal and the UK was recognised to have failed to meet its obligations until enactment of the 2010 Bribery Act.

Download full PDF article here >

For further details please contact Alison Dennis, Partner or Tony Lewis, Partner at Field Fisher Waterhouse LLP